AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18468273 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study 16536815 — intervention group
Group type: EXPERIMENTAL
Intervention: LED system (40 J cm(‐2); 80 mW cm(‐2))
Number of subjects: 40
Study 16536815 — intervention group
Group type: COMPARATOR
Intervention: Incoherent lamp (100 J cm(‐2); 160 mW cm(‐2))
Number of subjects: 40
Study 16536815 — intervention group
Group type: EXPERIMENTAL
Intervention: LED system
Number of subjects: 40
Study 16536815 — intervention group
Group type: COMPARATOR
Intervention: Incoherent lamp
Number of subjects: 40
Study 12680079 — intervention group
Group type: EXPERIMENTAL
Intervention: All-ceramic restorations
Number of subjects: 0
Study 11706694 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly-L-lactic acid screws
Number of subjects: 91
Study 11706694 — intervention group
Group type: COMPARATOR
Intervention: Titanium screws
Number of subjects: 91
Study 9770556 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy milk
Number of subjects: 65
Study 9770556 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 65
Study 9770556 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to soy milk
Number of subjects: 65
Study 7921429 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol treatment
Number of subjects: 9
Study 7921429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3166046 — intervention group
Group type: EXPERIMENTAL
Intervention: Red rubber urethral catheter (RRUC)
Number of subjects: 0
Study 3166046 — intervention group
Group type: COMPARATOR
Intervention: Acrylic stent
Number of subjects: 0
Study 3166046 — intervention group
Group type: COMPARATOR
Intervention: No stabilization
Number of subjects: 0
Study 31039001 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-infused highly crosslinked polyethylene insert (study group)
Number of subjects: 200
Study 31039001 — intervention group
Group type: COMPARATOR
Intervention: Conventional polyethylene insert (control group)
Number of subjects: 200
Study 28329223 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app follow-up care
Number of subjects: 65
Study 28329223 — intervention group
Group type: COMPARATOR
Intervention: In-person follow-up care
Number of subjects: 65
Study 25499302 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with sirolimus-eluting stents (SES)
Number of subjects: 130
Study 25499302 — intervention group
Group type: COMPARATOR
Intervention: MIDCAB surgery
Number of subjects: 130
Study 25499302 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 130
Study 23446962 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (HPD), 1.2 g·kg BW(-1)·d(-1)
Number of subjects: 72
Study 23446962 — intervention group
Group type: COMPARATOR
Intervention: Normal-protein diet (NPD), 0.8 g·kg BW(-1)·d(-1)
Number of subjects: 72
Study 22080658 — intervention group
Group type: EXPERIMENTAL
Intervention: Glove use
Number of subjects: 7578
Study 22080658 — intervention group
Group type: COMPARATOR
Intervention: No glove use
Number of subjects: 7578
Study 19061937 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 10
Study 19061937 — intervention group
Group type: COMPARATOR
Intervention: Non-penetrating placebo needles
Number of subjects: 10
Study 16519594 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex messages promoting fruit and vegetable consumption
Number of subjects: 517
Study 16519594 — intervention group
Group type: COMPARATOR
Intervention: Simple messages promoting fruit and vegetable consumption
Number of subjects: 517
Study 15257930 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT) after induction therapy with idarubicin, cytarabine, and etoposide.
Number of subjects: 258
Study 15257930 — intervention group
Group type: COMPARATOR
Intervention: Candidates not undergoing ASCT.
Number of subjects: 258
Study 15257930 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with idarubicin, cytarabine, and etoposide.
Number of subjects: 258
Study 15257930 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) for patients with unfavorable cytogenetics, age over 70 years, or leukocytosis.
Number of subjects: 258
Study 11464255 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 64
Study 11464255 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 64
Study 11464255 — intervention group
Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 64
Study 9283510 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam-exposure
Number of subjects: 129
Study 9283510 — intervention group
Group type: COMPARATOR
Intervention: Placebo-exposure
Number of subjects: 129
Study 9283510 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam-relaxation
Number of subjects: 129
Study 9283510 — intervention group
Group type: COMPARATOR
Intervention: Placebo-relaxation
Number of subjects: 129
Study 9283510 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' classifications in alprazolam group
Number of subjects: 129
Study 9283510 — intervention group
Group type: COMPARATOR
Intervention: Patients' classifications in placebo group
Number of subjects: 129
Study 29671767 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein Hydrolysate (3.3, 5.0, or 7.5 g of protein)
Number of subjects: 11
Study 29671767 — intervention group
Group type: COMPARATOR
Intervention: Free Amino Acid Mixture (2.5 g)
Number of subjects: 11
Study 27644034 — intervention group
Group type: EXPERIMENTAL
Intervention: EBA-175 RII-NG vaccine (5 μg, 20 μg, or 80 μg) administered intramuscularly at 0, 1, and 6 months
Number of subjects: 52
Study 27644034 — intervention group
Group type: EXPERIMENTAL
Intervention: EBA-175 RII-NG vaccine
Number of subjects: 52
Study 27644034 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 52
Study 25425377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic classification of chorionicity
Number of subjects: 545
Study 25425377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic examinations before 14 weeks' gestation
Number of subjects: 545
Study 25425377 — intervention group
Group type: EXPERIMENTAL
Intervention: Each week increase in gestational age
Number of subjects: 545
Study 22781642 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy followed by surgery (arm A)
Number of subjects: 123
Study 22781642 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (arm B)
Number of subjects: 123
Study 19458364 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole plus aspirin (200 mg dipyridamole and 25 mg aspirin, twice daily)
Number of subjects: 649
Study 19458364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 649
Study 16951298 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (N = 11), prescribed a conditioning program of aerobic and lower-body resistance training 3 days per week.
Number of subjects: 41
Study 16951298 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 12)
Number of subjects: 41
Study 15532134 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive patch (20 micrograms of ethinylestradiol and 150 micrograms of norelgestromin)
Number of subjects: 3300
Study 15532134 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive patch
Number of subjects: 3300
Study 17690815 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubular bandaging material
Number of subjects: 15
Study 17690815 — intervention group
Group type: COMPARATOR
Intervention: Short‐stretch medical compression bandages
Number of subjects: 15
Study 17690815 — intervention group
Group type: COMPARATOR
Intervention: Long‐stretch medical compression bandages
Number of subjects: 15
Study 9597955 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary surgery (laryngectomy) and radiotherapy (RT)
Number of subjects: 332
Study 9597955 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy (CT) and radiotherapy (RT)
Number of subjects: 332
Study 9597955 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laryngectomy patients
Number of subjects: 332
Study 7941816 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2 in 2.5 ml Triacetin gel (Prepidil) intracervically in the evening (10.00 p.m.)
Number of subjects: 100
Study 7941816 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg PGE2 in 2.5 ml Triacetin gel (Prepidil) intracervically in the morning (6.00 a.m.)
Number of subjects: 100
Study 7941816 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2 in 2.5 ml Triacetin gel (Prepidil) in the evening (10.00 p.m.)
Number of subjects: 100
Study 7941816 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg PGE2 in 2.5 ml Triacetin gel (Prepidil) in the morning (6.00 a.m.)
Number of subjects: 100
Study 3258862 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin
Number of subjects: 56
Study 3258862 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 56
Study 29895954 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-α 450 IU/kg/week
Number of subjects: 130
Study 29895954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 28825515 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg-based, trivalent, inactivated split influenza vaccine
Number of subjects: 1390
Study 28825515 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 1390
Study 25764482 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical natamycin, 5%
Number of subjects: 323
Study 25764482 — intervention group
Group type: COMPARATOR
Intervention: Topical voriconazole, 1%
Number of subjects: 323
Study 25764482 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical natamycin, 5% (subgroup analysis for Fusarium species)
Number of subjects: 323
Study 25764482 — intervention group
Group type: COMPARATOR
Intervention: Topical voriconazole, 1% (subgroup analysis for Fusarium species)
Number of subjects: 323
Study 25764482 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical natamycin, 5% (for Aspergillus or other non-Fusarium species)
Number of subjects: 323
Study 25764482 — intervention group
Group type: COMPARATOR
Intervention: Topical voriconazole, 1% (for Aspergillus or other non-Fusarium species)
Number of subjects: 323
Study 22990223 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of nicotine replacement therapy (NRT)
Number of subjects: 633
Study 22990223 — intervention group
Group type: COMPARATOR
Intervention: Lower doses of nicotine replacement therapy (NRT)
Number of subjects: 633
Study 20529203 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management workshop (6-week intervention, weekly 2-hour sessions based on cognitive-behavioral principles)
Number of subjects: 132
Study 20529203 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management workshop
Number of subjects: 132
Study 20529203 — intervention group
Group type: COMPARATOR
Intervention: Information-only intervention
Number of subjects: 132
Study 18563636 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher OEF regions (OEF > 50)
Number of subjects: 8
Study 18563636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower OEF regions (OEF < 30)
Number of subjects: 8
Study 18563636 — intervention group
Group type: EXPERIMENTAL
Intervention: High OEF regions (OEF > 70)
Number of subjects: 8
Study 18563636 — intervention group
Group type: EXPERIMENTAL
Intervention: One subject in high OEF region (>70)
Number of subjects: 8
Study 16415448 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic Arnica montana
Number of subjects: 29
Study 16415448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 15223002 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA (400 mg) + CarbiDOPA (100 mg)
Number of subjects: 8
Study 11509480 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity cycling for 8 weeks
Number of subjects: 20
Study 11509480 — intervention group
Group type: COMPARATOR
Intervention: Sedentary activity for 8 weeks
Number of subjects: 20
Study 11509480 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 9007745 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe carotid stenosis
Number of subjects: 384
Study 9007745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild or moderate carotid disease
Number of subjects: 384
Study 9007745 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan showing infarction
Number of subjects: 384
Study 8329922 — intervention group
Group type: EXPERIMENTAL
Intervention: Active opportunistic testing
Number of subjects: 5529
Study 8329922 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive opportunistic testing
Number of subjects: 5529
Study 8329922 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing by appointment after letter invitation
Number of subjects: 5529
Study 8329922 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing by appointment after letter and leaflet invitation
Number of subjects: 5529
Study 8329922 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing by appointment after late letter invitation
Number of subjects: 5529
Study 8329922 — intervention group
Group type: EXPERIMENTAL
Intervention: Active opportunistic testing by appointment
Number of subjects: 5529
Study 8329922 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive test result
Number of subjects: 5529
Study 8329922 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative test result
Number of subjects: 5529
Study 2434802 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4, 8, and 16 mg)
Number of subjects: 0
Study 2434802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31846808 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 I.U.)
Number of subjects: 113
Study 31846808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 31846808 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD patients
Number of subjects: 113
Study 31846808 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole sample
Number of subjects: 113
Study 30963205 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1 mg/kg IV
Number of subjects: 214
Study 30963205 — intervention group
Group type: COMPARATOR
Intervention: Saline IV
Number of subjects: 214
Study 28430326 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurus system (group 1)
Number of subjects: 61
Study 28430326 — intervention group
Group type: COMPARATOR
Intervention: Constellation system (group 2)
Number of subjects: 61
Study 25646057 — intervention group
Group type: EXPERIMENTAL
Intervention: Stromal hydration
Number of subjects: 60
Study 25646057 — intervention group
Group type: COMPARATOR
Intervention: No stromal hydration
Number of subjects: 60
Study 24329696 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen only (n=168)
Number of subjects: 885
Study 24329696 — intervention group
Group type: COMPARATOR
Intervention: Combined estrogen-progesterone (n=117)
Number of subjects: 885
Study 24329696 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal women without HT (n=360)
Number of subjects: 885
Study 24329696 — intervention group
Group type: COMPARATOR
Intervention: Premenopausal women (n=140)
Number of subjects: 885
Study 24329696 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen substitution therapy (follow-up study)
Number of subjects: 885
Study 22058298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented prosthesis
Number of subjects: 50
Study 22058298 — intervention group
Group type: COMPARATOR
Intervention: Cementless prosthesis
Number of subjects: 50
Study 19339404 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut diet (42.5 g walnuts/10.1 mJ)
Number of subjects: 25
Study 19339404 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish diet (113 g salmon, twice/wk)
Number of subjects: 25
Study 19339404 — intervention group
Group type: COMPARATOR
Intervention: Control diet (no nuts or fish)
Number of subjects: 25
Study 16905208 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation (45Gy in 25 fractions + 5-FU)
Number of subjects: 30
Study 15577135 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 11730735 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐pertechnetate vaginally (0.2 mL)
Number of subjects: 6
Study 11730735 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐pertechnetate vaginally (0.2 mL) with sealed cervical canal
Number of subjects: 6
Study 11730735 — intervention group
Group type: COMPARATOR
Intervention: (99m)Tc‐pertechnetate intravenously
Number of subjects: 6
Study 9200272 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 40 mg per day
Number of subjects: 20
Study 9200272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8254957 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conserving treatment, quadrantectomy with or without immediate reconstruction, axillary dissection, internal mammary biopsy, and breast irradiation
Number of subjects: 0
Study 8254957 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 2888736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 23-0364 (0.25 mg)
Number of subjects: 10
Study 2888736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 23-0364 (0.5 mg)
Number of subjects: 10
Study 2888736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 23-0364 (1.0 mg)
Number of subjects: 10
Study 2888736 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 10
Study 2888736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30357556 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid switching
Number of subjects: 498
Study 28901662 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypoxia (end-tidal PO2 74 ± 2 mmHg)
Number of subjects: 30
Study 28901662 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypoxia (end-tidal PO2 50 ± 3 mmHg)
Number of subjects: 30
Study 28901662 — intervention group
Group type: EXPERIMENTAL
Intervention: GTN-induced dilatation during mild hypoxia
Number of subjects: 30
Study 28901662 — intervention group
Group type: EXPERIMENTAL
Intervention: GTN-induced dilatation during moderate hypoxia
Number of subjects: 30
Study 28901662 — intervention group
Group type: COMPARATOR
Intervention: Normoxic time control (30 min)
Number of subjects: 30
Study 25219699 — intervention group
Group type: EXPERIMENTAL
Intervention: GreenLight XPS
Number of subjects: 291
Study 25219699 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate
Number of subjects: 291
Study 24463577 — intervention group
Group type: EXPERIMENTAL
Intervention: ePREP (computer-based preventive intervention)
Number of subjects: 52
Study 24463577 — intervention group
Group type: COMPARATOR
Intervention: Active placebo control group
Number of subjects: 52
Study 22565005 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with chemotherapy
Number of subjects: 774
Study 22565005 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 774
Study 22565005 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with chemotherapy
Number of subjects: 774
Study 19724045 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequately registered trials (147 trials)
Number of subjects: 323
Study 19724045 — intervention group
Group type: COMPARATOR
Intervention: Trials lacking registration (89 trials)
Number of subjects: 323
Study 19724045 — intervention group
Group type: COMPARATOR
Intervention: Trials registered after completion (45 trials)
Number of subjects: 323
Study 19724045 — intervention group
Group type: COMPARATOR
Intervention: Trials with unclear primary outcomes (39 trials)
Number of subjects: 323
Study 19724045 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with discrepancies (46 trials)
Number of subjects: 323
Study 19724045 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistically significant results in discrepancies (23 trials)
Number of subjects: 323
Study 17541059 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent body fat
Number of subjects: 32
Study 17541059 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 32
Study 17541059 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa subtype
Number of subjects: 32
Study 17541059 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-hip ratio
Number of subjects: 32
Study 17541059 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cortisol levels
Number of subjects: 32
Study 17541059 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum leptin levels
Number of subjects: 32
Study 15383114 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hysterectomy
Number of subjects: 279
Study 15383114 — intervention group
Group type: COMPARATOR
Intervention: Subtotal hysterectomy
Number of subjects: 279
Study 12128107 — intervention group
Group type: COMPARATOR
Intervention: 70 Gy
Number of subjects: 301
Study 12128107 — intervention group
Group type: EXPERIMENTAL
Intervention: 78 Gy
Number of subjects: 301
Study 12128107 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 301
Study 9850489 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide gastrointestinal therapeutic system (GITS)
Number of subjects: 569
Study 9850489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 569
Study 7924707 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloanal anastomosis
Number of subjects: 29
Study 7924707 — intervention group
Group type: COMPARATOR
Intervention: Ileoanal anastomosis
Number of subjects: 29
Study 2679967 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restrictions during Haemoccult retesting
Number of subjects: 18925
Study 2679967 — intervention group
Group type: COMPARATOR
Intervention: Normal diet during initial Haemoccult testing
Number of subjects: 18925
Study 2679967 — intervention group
Group type: EXPERIMENTAL
Intervention: Retesting after 3 months with dietary restrictions
Number of subjects: 18925
Study 1245939 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated monovalent influenza B vaccine (0.25 ml containing 250 chick cell agglutinating units)
Number of subjects: 45
Study 30663593 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin with chemotherapy
Number of subjects: 0